Methods of treating urogenital-neurological disorders using modified clostridial toxins

Details for Australian Patent Application No. 2008316989 (hide)

Owner Allergan, Inc.

Inventors Brin, Mitchell F.; Francis, Joseph; Aoki, Kei Roger

Agent Davies Collison Cave

Pub. Number AU-A-2008316989

PCT Pub. Number WO2009/055351

Priority 61/076,228 27.06.08 US; 60/982,021 23.10.07 US

Filing date 21 October 2008

Wipo publication date 30 April 2009

International Classifications

A61K 38/16 (2006.01) Medicinal preparations containing peptides - Peptides having more than 20 amino acids

A61K 35/74 (2006.01) Medicinal preparations containing material or reaction products thereof with undetermined constitution

A61P 13/10 (2006.01) Drugs for disorders of the urinary system

Event Publications

20 May 2010 PCT application entered the National Phase

  PCT publication WO2009/055351 Priority application(s): WO2009/055351

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008317000-Probiotic compositions and methods for inducing and supporting weight loss

2008316988-Methods of treating chronic neurogenic inflammation using modified clostridial toxins